CASE REPORT
===========

A 49-year-old African American male presents with a large mass on the left shoulder that has been rapidly enlarging for the past 2 months. The mass grew over a presumed keloid scar, which developed approximately 1 month following a motor vehicle accident 12 years prior. During the accident, he suffered a contusion to the left shoulder that first bruised and subsequently formed a golf ball-sized mass. There was no breakage of skin on the left shoulder. He sought medical attention for the skin lesion at that time and was diagnosed with keloid, which was readily accepted as he had past medical history and similar family history. No treatment for the lesion was performed at that time. Since then, the lesion had been stable without any change in shape, color, or size until 1.5 years prior to evaluation, when he suffered a minor trauma to the lesion during a work-related injury that did not break the skin barrier. Following this event, he noticed that the lesion slowly increased in size under the skin without apparent cutaneous changes in appearance. Two months before the clinical encounter, he noticed a new rapidly growing nodule on the surface of the initial mass. He noticed no changes in symptomatology other than left shoulder pain and limited range of motion of the neck that became more prominent as the mass increased in size.

On examination, there were three discrete protuberant tumor nodules, gray-white, involving the skin and subcutis. The largest nodule measured 16 × 15 × 7 cm and the smallest nodule measured 7 × 6 × 3 cm ([Figure 1](#g01){ref-type="fig"}).

![Resection of the lesion was performed with wide surgical margins from the left mid-clavicular region. The largest mass measured 16 × 15 × 7 cm and the smallest mass measured 7 × 6 × 3 cm.](autopsy-08-04e2018039-g01){#g01}

The tumor was ulcerated and necrotic without apparent attachment to underlying structures. Anterior cervical, posterior cervical, supraclavicular, and axillary lymph nodes were not palpable bilaterally, and there were no other masses observed. CT of thorax suggested the masses were superficial with no attachment to underlying bone or great vessels, and there was no evidence of metastatic disease or adenopathy. A wide excisional biopsy of the lesion was performed. The histological examination revealed a fascicular architectural pattern composed of plump spindle cells with high nuclear grade atypia and numerous mitoses leading to the diagnosis of high-grade fibrosarcoma arising from DFSP ([Figure 2A](#g02){ref-type="fig"}). The spindle cells diffusely express CD34 ([Figure 2B](#g02){ref-type="fig"}).

![Photomicrograph of resected mass. **A --** demonstrates fibrosarcomatous differentiation of DFSP with cellular atypia with abundant mitotic activity (H&E, 40X); **B --** Immunohistochemistry staining for CD34 marker is diffusely expressed in the spindle cells and highlights the fascicular pattern of this tumor (20x).](autopsy-08-04e2018039-g02){#g02}

There were areas showing a transition from scar to DFSP ([Figure 3](#g03){ref-type="fig"}), and focal areas were consistent with keloid.

![Photomicrograph of the edge of the lesion shows transition between collagen-rich scar and proliferating spindle cells (HE, 10X).](autopsy-08-04e2018039-g03){#g03}

There was also invasion of the lesion into the underlying skeletal muscle as well as focal areas at the deep surgical margin. The post-op course was uneventful. Due to the location and extent of the invasion, further excision was not feasible. A multidisciplinary approach including radiation oncology will be pursued for further treatment. The current plan involves the placement of a skin graft over the incision site followed by radiation treatment to target the remaining lesion. The patient will continue to be observed for recurrence of the tumor to allow for early resection.

DISCUSSION
==========

Dermatofibrosarcoma protuberans (DFSP) is a relatively rare soft tissue sarcoma withan estimated overall annual incidence of 4.2 cases per one million persons per year. Black people are affected at almost 2 times the rate of whites, and incidence among women is 1.14 times higher than among men.[@B001] Trauma has been hypothesized as a predisposing factor for DFSP, with reported cases of tumors arising from vaccination sites, burn scars, and surgical scars.[@B002] These studies[@B003]^-^[@B006] document roughly 10% of patients providing a history of antecedent traumatic insult; however, mechanistic basis and clear causative relationship have not been identified.[@B007] DFSP accounts for less than 0.1% of all malignant neoplasms, but it is the most common type of skin sarcoma. The lesion most commonly appears on the trunk, proximal extremities, and the head and neck. Initially, the tumor may appear as a sclerotic plaque-like mass with bluish skin discoloration which can be misinterpreted as a keloid. The tumor may show an initial slow growth phase for several years characterized by lateral spread before reaching a rapid growth phase with vertical infiltration and fixation to deep structures. As the mass enlarges, the overlying skin may ulcerate and bleed.[@B008] Fibrosarcomatous transformation in DFSP represents tumor progression marked by a more aggressive clinical behavior with higher rates of local recurrence and metastasis.[@B009]^,^[@B010] Histopathology of fibrosarcomatous foci demonstrates higher cellularity and fascicular pattern of growth rather than the storiform pattern normally seen in DFSP.[@B011]

Molecular studies have demonstrated that most cases of DFSP can be differentiated from other dermatofibromas by the presence of a t(17;22)(q22;q13) translocation forming a PDGFB/COL1A1 fusion gene containing a protein of a collagen 1 subunit and a platelet derived growth factor (PDGF) subunit. The translocation has been demonstrated to be present in up to 90% of cases and is a very useful marker for differential diagnosis.[@B012] Additionally, DFSPs with higher proportions of histologically fibrosarcomatous zones have been demonstrated to have a higher proportion of the translocation. Research investigating the significance of the translocation is still being conducted; nevertheless, the detection of the fusion gene using fluorescence in-situ hybridization (FISH) currently serves as an additional modality of DFSP diagnosis.

Surgical resection remains the treatment of choice, which can be achieved with standard wide local excision with negative margins or Mohs micrographic surgery.[@B007]^,^[@B013] Currently, a 2-3 cm margin is recommended for resection, and radiotherapy has been postulated as an option for adjuvant therapy, especially in the setting of positive surgical margins when further resection is not feasible.[@B014]^,^[@B015] Chemotherapy with imatinib mesylate has been used with demonstrable disease regression in DFSP; however, its efficacy and durability for the treatment of FS-DFSP is limited, with most cases showing initial response followed by relapse.[@B016]

Although DFSP rarely metastasizes, FS-DFSP has a reported metastatic rate of between 14% and 18%.[@B010]^,^[@B017] Both disease processes can be locally invasive and has a high rate of local recurrence after surgical excision. According to the review of 913 DFSP cases by Rutgers et al.,[@B018] recurrence after adequate wide excision was 13% compared to the overall recurrence rate of about 50%. Given the tendency for rapid growth, local invasion, recurrence, and cosmetic disfigurement, locally malignant processes such as DFSP should be suspected when patients present with perceived changes in previously stable lesions, even when prior history of trauma clearly predated the skin lesion. Furthermore, because our case demonstrates that DFSP may arise from an underlying scar, clinicians should maintain clinical suspicion of changing lesions even in the setting of biopsy proven benign lesions.

**How to cite:** Lee SW, Zaesim A, Jackson A, Borkat M. Fibrosarcomatous dermatofibrosarcoma protuberans from scar following trauma. Autops Case Rep \[Internet\]. 2018;8(4):e2018039. <https://doi.org/10.4322/acr.2018.039>

All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Financial support: None

[^1]: Author contributions: Lee SW provided the main research, data gathering, and writing of article, Zaesim A and Jackson A helped format and write sections of the article such as discussion, Borkat M led the clinical management of the patient.

[^2]: Conflict of interest: None
